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ABsTrACT
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing 
interstitial lung disease of unknown aetiology which leads 
rapidly to death. As diagnosis of IPF is complex, we aimed 
to characterise microRNA (miRNA) content of exosomes 
from sputum of patients with IPF. Using miRNA quantitative 
PCR array, we found a substantial dysregulation of sputum 
exosomal miRNA levels between patients with IPF and 
healthy subjects and identified a unique signature of three 
miRNAs. Interestingly, we found a negative correlation 
between miR-142-3p and diffusing capacity of the lungs 
for carbon monoxide/alveolar volume. This is the first 
characterisation of miRNA content of sputum-derived 
exosomes in IPF that identified promising biomarkers for 
diagnosis and disease severity.
BACkground
Idiopathic pulmonary fibrosis (IPF) is a progres-
sive fibrosing interstitial lung disease of unknown 
Figure 1 Identification of a subset of exosomal microRNAs (miRNAs) dysregulated in the sputum of patients with 
idiopathic pulmonary fibrosis (IPF). Characterisation of exosome-like vesicles released from sputum by (A) transmission 
electron microscopy, (B) dynamic light scattering analysis (140±19.1 nm, n=3) and (C) western blotting. Presence of 
exosomal markers, CD63, CD9, CD81 and mitochondrial protein cytochrome c in lysates from sputum-derived exosomes 
and cell lysate. (D) Principal component analysis plot on miRNA expression data from sputum-derived exosomes from 
healthy subjects (HS) and patients with IPF. (E) Volcano plot and (F) heat map of differentially expressed miRNAs across 
sputum-derived exosomes from HS and patients with IPF (fold change >1.3 and p<0.05). (G) Diseases and disorders or 
(H) functions annotation associated with exosomal miRNAs dysregulated in the sputum of patients with IPF predicted 
by ingenuity pathway analysis.
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aetiology which leads rapidly to death.1 As diagnosis of IPF is 
complex, the search for novel biomarkers is a central challenge 
for the future of translational research.2 Induced sputum has 
been previously identified as a potential biofluid of interest in 
IPF.3 A growing list of studies reported the presence of a specific 
type of extracellular vesicles, exosomes, in several biofluids 
(including blood, bronchoalveolar lavage fluid, saliva) and an 
alteration of their composition during the course of diseases,4–6 
highlighting the value of these vesicles as a new source of 
biomarkers. Most of the studies performed so far have searched 
for exosomal markers in sera or plasma samples, while only one 
recent study reported the presence of exosomes in the sputum of 
patients with asthma.7 The aim of our study was to characterise 
microRNA (miRNA) content of sputum exosomes of patients 
with IPF versus healthy subjects (HS) in order to identify novel 
diagnostic biomarkers.
MeThods
For full technical details, see the online Supplementary data. 
Patients with IPF were recruited from the ambulatory care poly-
clinics of both Liège University. All subjects gave written consent 
before their enrolment. The patient characteristics are summa-
rised in the online Supplementary table S1. After collecting 
the induced sputum, exosomes were isolated from the sputum 
supernatant by using a standard ultracentrifugation protocol.
resulTs
The isolated vesicles present a spherical morphology 
(figure 1A), an average size distribution of 140 nm (±19.1 nm) 
(figure 1B), an enrichment of several exosomal markers, CD63, 
CD9 and CD81 and an absence of mitochondrial cytochrome 
C (figure 1C), which clearly indicate that this vesicle popu-
lation is enriched in exosomes. The miRNA expression 
profiling of sputum-derived exosomes from six patients with 
IPF and six HS by miRNA quantitative PCR arrays allowed 
us to identified 21 miRNAs differentially expressed, among 
which seven miRNAs were upregulated and 14 miRNAs were 
downregulated in patients with IPF (figure 1D–F and online 
Supplementary table S2). In order to assess whether some 
dysregulated miRNAs correlate with the pathophysiology of 
the disease, we subjected a list of seven miRNAs with aber-
rant expression (three upregulated miRNAs: miR-33a-5p, 
miR-142–3 p and miR-192–5 p; four downregulated miRNAs: 
let-7d-5p, miR-26a-5p, miR-29b-3p and miR-423-3p) to inge-
nuity pathway analysis tool. The results indicated that these 
miRNAs are involved in the development of inflammatory 
diseases, among which the IPF disease is the most relevant 
one (p=3.78E−10) (figure 1G, H). The functional analysis of 
Figure 2 Diagnostic value of sputum-derived exosomal miR-142-3 p, miR-33a-5p and let-7d-5p for idiopathic pulmonary fibrosis (IPF) disease. 
(A) Quantitative real-time PCR analysis of differentially expressed microRNAs (miRNAs) in sputum-derived exosomes from patients with IPF (n=16) 
compared with healthy subjects (HS; n=14). Cohort 1 was used to identify exosomal miRNAs dysregulated in the sputum of patients with IPF; cohort 
2 is the validation cohort. (B) Receiver operator characteristic (ROC) curves with (C) corresponding area under the curves (AUCs) for comparing the 
ability of miR-142-3 p, miR-33a-5p and let-7d-5p to discriminate patients with IPF versus HS. ROC curves were constructed by combining the two 
cohorts (cohort 1 and cohort 2). Five logistic regression models were generated: (1) model 1: age and sex; (2) model 2: model 1+miR-33a-5p; (3) 
model 3: model 1+let-7d-5p; (4) model 4: model 1+miR-142-3p and (5) model 5: model 1+miR-33a-5P+let-7d-5P+miR-142-5 p.
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their predicted targets revealed that these regulators play key 
roles in several pathophysiological processes involved in the 
initiation and progression of IPF disease, such as deposition 
of extracellular matrix, collagen secretion and epithelial to 
mesenchymal transition (online Supplementary figure S1).
We further validated three promising biomarker candidates 
(miR-142-3 p, miR-33a-5p, let-7d-5p) by quantitative real-
time-PCR in an independent cohort (cohort 2) consisting of 10 
patients with IPF and eight HS (online Supplementary figure 
S2). By combining the two cohorts, we observed significantly 
increased levels of miR-142-3p and miR-33a-5p (9.4 and 3.13 
fold, respectively) and decreased levels of let-7d-5p (0.49-fold) 
in sputum-derived exosomes from patients with IPF (n=16) 
compared with HS (n=14) (figure 2A). The results were not 
altered after adjusting for age or gender distribution (online 
Supplementary tables S3 and S4).
To investigate their diagnostic value, we constructed receiver 
operator characteristic (ROC) curves using logistic regression 
models with adjustment for age and sex for each altered miRNAs 
(figure 2B). The area under the ROC curve (AUC) of the model 
1, comprising age and sex, was 0.864 (95% CI 0.735 to 0.993, 
p<0.001) (figure 2C). The addition of miR-33a-5p, let-7d-5p 
or miR-142-3p to the model increased the AUC to 0.933 (95% 
CI 0.848 to 1.000, p<0.0001), 0.942 (95% CI 0.865 to 1.000, 
p<0.0001) and 0.964 (95% CI 0.893 to 1.000, p<0.0001), 
respectively (figure 2C). When combining the three miRNAs, 
the AUC reaches 0.978 (95% CI 0.930 to 1.000, p<0.0001) 
suggesting that this miRNA signature may be useful for IPF 
detection and diagnosis.
Then, the correlation between the expression level of sputum 
exosomal miRNAs and lung function was studied in the group 
of patients with IPF. Correlation studies revealed a negative 
correlation between diffusing capacity of the lungs for carbon 
monoxide/alveolar volume (DLCO/VA) and miR-142-3p 
(r=−0.68, p=0.010) and a positive one with let-7d-5p (r=0.55, 
p=0.048) (figure 3). All these observations suggest that sputum 
exosomal miRNAs are associated with the severity of lung 
disease in the particular case of patients with IPF.
disCussion
We identified for the first time miRNAs modifications from 
sputum-derived exosomes in patients with IPF as potential 
biomarkers correlated with disease severity. We propose a novel 
signature composed of three miRNAs (miR-142-3p, miR-33a-5p, 
let-7d-5p) to discriminate with a high specificity and sensibility 
patients with IPF of HS.
One of the main finding of our research is the negative corre-
lation observed for miR-142-3p with lung function assessed 
by DLCO/VA, a marker of alveolo-capillar function, whereas 
let-7d-5p goes in the opposite direction. This observation 
suggests that those miRNAs are not only promising biomarkers 
but also putative players in the disease.
Interestingly, miR-142-3p was shown to contribute to the 
proper proliferation of mesenchymal progenitors by controlling 
WNT signalling.8 Elevated levels of miR-142-3p might thus 
lead to an altered balance between mesenchymal cell prolifera-
tion and differentiation, a feature observed during IPF progres-
sion. Furthermore, let-7d-5p downregulation has been widely 
reported as primordial miRNA involved IPF pathophysiology, by 
contributing to epithelial mesenchymal transition in lung epithe-
lial cells.9 Of note, miR-33a-5p has been recently implicated in 
liver fibrosis.10 This observation deserves further investigations 
on the role of this miRNA in lung fibrosis.
Our study identified miRNAs previously identified in plasma 
as well as new miRNAs with potential functional role in IPF 
progression. Our findings may thus lead to a better under-
standing about the roles of identified sputum exosomal miRNAs 
Figure 3 Correlation analysis of lung function and sputum-derived 
exosomal microRNAs (miRNAs) in patients with idiopathic pulmonary 
fibrosis (IPF). Correlation between diffusing capacity of the lungs for 
carbon monoxide (DLCO)/alveolar volume (VA) (%pred) and miRNA 
levels in patients with IPF.
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in IPF pathogenesis and thus open new avenues for thera-
peutic approaches. Unfortunately, the cross-sectional design of 
our study does not allow the identification of predictive and/
or prospective biomarkers. Further longitudinal studies will be 
performed to validate the potential of sputum exosomal miRNAs 
as biomarkers in IPF to predict disease severity and evolution.
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